ArticleInternational journal of retina and vitreous2025
Outcomes of subretinal macular hemorrhage treatment: a 7-year retrospective cohort study at Oslo University Hospital.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSubretinal macular hemorrhage (SRMH) is a vision-threatening condition with no consensus on optimal treatment. This study evaluated the outcomes of five treatment modalities and their correlation with patient characteristics and optical coherence tomography findings.
methodsA retrospective review was conducted on 120 SRMH patients treated at Oslo University Hospital between October 24, 2015, and December 27, 2022. Best-corrected visual acuity (BCVA) was assessed before and 1-month after treatment. Statistical analyses were performed to evaluate the impact of treatment timing, hemorrhage size, and different therapeutic interventions on visual outcomes.
resultsEarly intervention, particularly within 7 days of symptom onset, was associated with better median BCVA 1-month post-surgery. A 14-day cut-off showed no benefit. Patients with smaller hemorrhages (< 4500 μm) had significantly higher BCVA before treatment, but no statistical difference was observed 1-month after treatment. Combination therapies, including tissue plasminogen activator (tPA) with Sulfur Hexafluoride (SF6) gas and tPA with SF6 gas plus anti-vascular endothelial growth factor (anti-VEGF), resulted in significantly improved visual outcomes 1-month post-surgery, but no intervention outperformed others at the 1-month endpoint.
conclusionsEarly intervention, particularly within 7 days of symptom onset, may improve visual outcomes in SRMH. Combined therapies involving tPA, gas and anti-VEGF appear to be more effective. Further studies with extended follow-up are needed to establish definitive treatment guidelines. TRANSLATIONAL RELEVANCE: This study highlights the importance of early intervention and individualized treatment strategies in managing SRMH. The findings contribute valuable insights into the effectiveness of combination therapies, offering guidance for clinicians and informing future research on evidence-based treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.